Sharps Technology Receives $30M Purchase Order From Nephron Pharmaceuticals For Syringes
Portfolio Pulse from Benzinga Newsdesk
Sharps Technology has received a $30 million purchase order from Nephron Pharmaceuticals for syringes. This order is part of a five-year, $200 million Syringe Sales Agreement. The first shipments of prefillable syringes are expected to begin by Q2 of 2025.
June 13, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sharps Technology has secured a $30 million purchase order from Nephron Pharmaceuticals, marking the first year of a five-year, $200 million Syringe Sales Agreement. This is a significant revenue boost and a strong partnership for Sharps Technology.
The $30 million purchase order is a substantial revenue boost for Sharps Technology and signifies a strong partnership with Nephron Pharmaceuticals. This agreement is likely to positively impact Sharps Technology's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100